Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)-Reference-Cited by-同舟云学术

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

Published:2023-09 Issue:3 Volume:84 Page:341-347
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Flaig Thomas W.^ORCID,Tangen Catherine M.,Daneshmand Siamak,Alva Ajjai Shivaram,Lucia M. Scott,McConkey David James,Theodorescu Dan,Goldkorn Amir,Milowsky Matthew I.,Bangs Rick,MacVicar Gary R.,Bastos Bruno R.,Fowles Jared S.,Gustafson Daniel L.,Plets Melissa,Thompson Ian M.,Lerner Seth P.

Funder

National Institutes of Health

National Cancer Institute

Publisher

Elsevier BV

Subject

Urology

Reference22 articles.

1. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology;Flaig;J Natl Compr Cancer Netw,2020

2. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N Engl J Med,2003

3. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database;Zaid;Urology,2014

4. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours;Sternberg;Eur J Cancer,2006

5. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kann beim muskelinvasiven Urothelkarzinom der Harnblase zukünftig auf die Zystektomie verzichtet werden?;Die Urologie;2024-08-14

2. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen;Urology;2024-06

3. Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient;American Society of Clinical Oncology Educational Book;2024-06

4. Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314;Translational Andrology and Urology;2024-03